Bracco Targets Cell Therapy Manufacturing with Bead-Free Microbubble Cell Processing
-
By
February 13, 2026
-
3 min
-
1
Bracco Imaging introduces a microbubble-based approach for cell therapy.
-
2
Technology aims to replace magnetic beads for cell selection.
-
3
Microbubbles reduce cellular stress and simplify workflows.
-
4
Manufacturing will occur at a GMP-compliant facility in Geneva.
-
5
Bracco is focused on partnerships for technology development.
-
6
The platform supports multistep enrichment workflows.
-
7
Technology will be showcased at Advanced Therapies Week 2026.
-
Bracco Imaging is entering the cell therapy manufacturing market with a novel microbubble-based technology intended to replace traditional magnetic beads used for cell selection and activation. This advanced platform utilizes clinically validated lipid-based microbubbles to enhance the efficiency of cell therapy production by streamlining upstream processes and minimizing cellular stress. The zero-footprint nature of the technology simplifies workflows and supports multistep enrichment strategies, potentially expanding applications in immune cell purification. Manufacturing will occur at a new GMP-compliant facility in Geneva, with further performance data expected as early-access partners participate in development.
-
1
Bracco Imaging introduces a microbubble-based approach for cell therapy.
-
2
Technology aims to replace magnetic beads for cell selection.
-
3
Microbubbles reduce cellular stress and simplify workflows.
-
4
Manufacturing will occur at a GMP-compliant facility in Geneva.
-
5
Bracco is focused on partnerships for technology development.
-
6
The platform supports multistep enrichment workflows.
-
7
Technology will be showcased at Advanced Therapies Week 2026.
Listen Tab content
